Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice

Vaccine

Volumn 26, Issue 4, 2008, Pages 552-561

  Wack, Andreas ^a   Baudner, Barbara C ^a   Hilbert, Anne K ^b   Manini, Ilaria ^c   Nuti, Sandra ^a   Tavarini, Simona ^a   Scheffczik, Hanno ^b   Ugozzoli, Mildred ^d   Singh, Manmohan ^d   Kazzaz, Jina ^d   Montomoli, Emanuele ^c   Del Giudice, Giuseppe ^a   Rappuoli, Rino ^a   O'Hagan, Derek T ^d  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b Novartis Vaccine   (Germany)

^c UNIVERSITY OF SIENA   (Italy)

^d MS X 600A   (United States)

Author keywords

Adjuvants; Influenza vaccine; T cell cytokine response

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; CALCIUM PHOSPHATE; CPG OLIGODEOXYNUCLEOTIDE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CALCIUM PHOSPHATES; CELL LINE; EMULSIONS; FEMALE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; LACTIC ACID; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; POLYGLYCOLIC ACID; POLYMERS; POLYSORBATES; SPLEEN; SQUALENE; TH1 CELLS; VACCINES, SUBUNIT;

EID: 37849039132     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.054     Document Type: Article

References (57)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 2 (2003) 179-186
2. Johnson N.P., and Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 76 1 (2002) 105-115
3. WHO. Avian Influenza A (H5N1) infection in humans. N Engl J Med 353 (2005) 1374-1385
4. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 4 (1982) 25-44
5. Nicholson K.G., Wood J.M., and Zambon M. Influenza. Lancet 362 9397 (2003) 1733-1745
6. Kang I., Hong M.S., Nolasco H., Park S.H., Dan J.M., Choi J.Y., et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol 173 1 (2004) 673-681
7. Goodwin K., Viboud C., and Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24 8 (2006) 1159-1169
8. Deng Y., Jing Y., Campbell A.E., and Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 172 6 (2004) 3437-3446
9. Boon A.C., Fringuelli E., Graus Y.M., Fouchier R.A., Sintnicolaas K., Iorio A.M., et al. Influenza A virus specific T cell immunity in humans during aging. Virology 299 1 (2002) 100-108
10. Bernstein E.D., Gardner E.M., Abrutyn E., Gross P., and Murasko D.M. Cytokine production after influenza vaccination in a healthy elderly population. Vaccine 16 18 (1998) 1722-1731
11. Mbawuike I.N., Acuna C.L., Walz K.C., Atmar R.L., Greenberg S.B., and Couch R.B. Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of IL-12. Mech Ageing Dev 94 1-3 (1997) 25-39
12. Alberti S., Cevenini E., Ostan R., Capri M., Salvioli S., Bucci L., et al. Age-dependent modifications of Type 1 and Type 2 cytokines within virgin and memory CD4(+) T cells in humans. Mech Ageing Dev 127 6 (2006) 560-566
13. Castle S., Uyemura K., Wong W., Modlin R., and Effros R. Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents. Mech Ageing Dev 94 1-3 (1997) 7-16
14. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176 10 (2006) 6333-6339
15. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23 Suppl. 1 (2005) S10-S25
16. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., and Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 9492 (2005) 1165-1174
17. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2 9 (2003) 727-735
18. Ott G., Radhakrishnan R., Fang J.-H., and Hora M. The adjuvant MF59: a ten year perspective. In: O'Hagan D. (Ed). Vaccine adjuvants: preparation methods and research protocols (2001), Humana Press, Totowa, NJ 211-228
19. Podda A., and Del Giudice G. MF59: a safe and potent adjuvant for human use. In: Schijns V.E., and O'Hagan D.T. (Eds). Immunopotentiators in modern vaccines (2006), Oxford, Academic Press 149-159
20. Podda A., and Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2 2 (2003) 197-203
21. Banzhoff A., Nacci P., and Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49 3 (2003) 177-184
22. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 23-24 (1999) 3094-3101
23. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 9272 (2001) 1937-1943
24. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 15 (2003) 1687-1693
25. WHO 2nd WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, 2006.
26. Stephenson I., Nicholson K.G., Bugarini R., Podda A., Wood J., Zambon M., et al. Cross reactivity to highly pathogenic avian influenza H5N1 viruses following vaccination with non-adjuvanted and MF-59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 4962-4970
27. Mabrouk T., and Ellis R.W. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine). Dev Biol (Basel) 110 (2002) 125-134
28. Aggerbeck H., and Heron I. Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines-I. Vaccine 13 14 (1995) 1360-1365
29. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., et al. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2SF162) to anionic PLG microparticles retains the structural integrity of the protein, while encapsulation in PLG microparticles does not. Pharm Res 21 12 (2004) 2148-2152
30. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 93 2 (2004) 273-282
31. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
32. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199 (2004) 201-216
33. Sugai T., Mori M., Nakazawa M., Ichino M., Naruto T., Kobayashi N., et al. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23 46-47 (2005) 5450-5456
34. Seo S.H., and Webster R.G. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 76 3 (2002) 1071-1076
35. Wong G.H., and Goeddel D.V. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 323 6091 (1986) 819-822
36. Ishizaka S.T., Piacente P., Silva J., and Mishkin E.M. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J Infect Dis 172 4 (1995) 1108-1111
37. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287 5458 (2000) 1664-1666
38. Schlesinger J.J., and Chapman S. Neutralizing F(ab′)2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol 76 Pt 1 (1995) 217-220
39. Arulanandam B.P., Mittler J.N., Lee W.T., O'Toole M., and Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 164 7 (2000) 3698-3704
40. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13 9 (2006) 981-990
41. Mozdzanowska K., Furchner M., Washko G., Mozdzanowski J., and Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 71 6 (1997) 4347-4355
42. Feng J.Q., Mozdzanowska K., and Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76 3 (2002) 1369-1378
43. Kazzaz J., Neidleman J., Singh M., Ott G., and O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 67 2-3 (2000) 347-356
44. Frentsch M., Arbach O., Kirchhoff D., Moewes B., Worm M., Rothe M., et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 11 10 (2005) 1118-1124
45. Singh M., Ugozzoli M., Kazzaz J., Chesko J., Soenawan E., Mannucci D., et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 10 (2006) 1680-1686
46. Mitchell D.K., Holmes S.J., Burke R.L., Duliege A.M., and Adler S.P. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 21 2 (2002) 133-138
47. McFarland E.J., Borkowsky W., Fenton T., Wara D., McNamara J., Samson P., et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis 184 10 (2001) 1331-1335
48. Borkowsky W., Wara D., Fenton T., McNamara J., Kang M., Mofenson L., et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis 181 3 (2000) 890-896
49. Coban C., Ishii K.J., Stowers A.W., Keister D.B., Klinman D.M., and Kumar N. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun 72 1 (2004) 584-588
50. Hayden F.G., Fritz R., Lobo M.C., Alvord W., Strober W., and Straus S.E. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 101 3 (1998) 643-649
51. Doherty P.C., Topham D.J., Tripp R.A., Cardin R.D., Brooks J.W., and Stevenson P.G. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 159 (1997) 105-117
52. Brown D.M., Roman E., and Swain S.L. CD4 T cell responses to influenza infection. Semin Immunol 16 3 (2004) 171-177
53. Graham M.B., and Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186 12 (1997) 2063-2068
54. Graham M.B., Braciale V.L., and Braciale T.J. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 180 4 (1994) 1273-1282
55. Bot A., Bot S., and Bona C.A. Protective role of gamma interferon during the recall response to influenza virus. J Virol 72 8 (1998) 6637-6645
56. Mbawuike I.N., Acuna C., Caballero D., Pham-Nguyen K., Gilbert B., Petribon P., et al. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell Immunol 173 1 (1996) 64-78
57. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22 23-24 (2004) 3136-3143